Table 3 Characteristics of patients with high plasma NGAL levels
| Â | All (NÂ =Â 51) | FR positive (NÂ =Â 36) | FR negative (NÂ =Â 15) | P value |
|---|---|---|---|---|
Age | 65 (55–76) | 63.5 (49–73) | 73 (61–78) | 0.08 |
Male/female | 34/17 | 24/12 | 10/5 | 1.00 |
APACHE II score | 20 (14–22) | 19.5 (15–22) | 20 (14–28) | 0.56 |
Chronic heart failure | 10 | 5 | 5 | 0.12 |
Furosemide use before ICU | 18 | 10 | 8 | 0.08 |
Dose of furosemide before ICU (mg) | 20 (15–40) | 40 (15–60) | 20 (12.5–40) | 0.52 |
Serum creatinine (mg/dl) | ||||
 Baseline | 0.83 (0.51–1.36) | 0.81 (0.49–1.13) | 1.24 (0.8–2.59) | 0.07 |
 At hospitalization | 1.1 (0.78–1.92) | 0.97 (0.69–1.7) | 1.81 (0.96–3.64) | 0.04 |
 At ICU admission | 1.26 (0.92–1.94) | 1.13 (0.78–1.48) | 1.56 (1.01–2.14) | 0.08 |
 At furosemide administration | 1.33 (0.99–1.94) | 1.17 (0.98–1.67) | 1.77 (1.26–2.77) | 0.03 |
 Serum albumin (g/dL) | 2.8 (2.3–3.1) | 2.8 (2.3–3.1) | 2.7 (2.3–3.2) | 0.79 |
AKI stage at ICU admission | 0.92 | |||
 No AKI | 20 | 15 | 5 |  |
 Stage 1 | 21 | 14 | 7 |  |
 Stage 2 | 10 | 7 | 3 |  |
AKI stage at furosemide administration | 0.80 | |||
 No AKI | 13 | 10 | 3 |  |
 Stage 1 | 24 | 16 | 8 |  |
 Stage 2 | 14 | 10 | 4 |  |
Length of hospitalization (days) | 42 (25–85) | 45 (26–90) | 33 (17–77) | 0.23 |
Length of ICU stays (days) | 6 (3–13) | 5 (3–9) | 12 (4–16) | 0.04 |
Plasma NGAL at furosemide administration (ng/ml) | 303 (199–495) | 274 (190–399) | 354 (260–576) | 0.26 |
Dose of furosemide (mg) | 20 (10–20) | 10 (10–20) | 40 (20–45) | < 0.01 |